Developer docs
API playgroundTry for free, no card

Search company profiles

Laurus Labs

Full company profile

uuid0002zgn

Namestring
Laurus Labs
Legal namestring
Laurus Labs Limited
Websiteurl
lauruslabs.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Laurus Labs Limited is a Hyderabad-based, publicly listed pharmaceutical manufacturer founded in 2005 that operates an integrated value chain spanning active pharmaceutical ingredient (API) development, finished dosage form manufacturing, and contract development and manufacturing (CDMO) services. The company is a global leader in anti-retroviral (ARV) APIs and operates 15 manufacturing sites across approximately 230 acres in Visakhapatnam with 8,200+ kiloliters of reactor capacity and 12 billion tablet/capsule annual capacity. Its portfolio is organized across five segments: pharmaceutical ingredients (ARV, oncology, cardiovascular, diabetes APIs), finished dosages, biologics and biotechnology (through subsidiary Laurus Bio's precision fermentation), non-human ingredients (animal health and agrochemicals through Laurus Synthesis), and rare disease therapeutics marketed in India under brands including TriLaWil, LASINONE, AMMOBULA, and Larglustat.

Laurus derives revenue through multiple streams: CDMO services for global pharmaceutical innovators, generic API and intermediate supply, finished dosage commercialization via wholly-owned subsidiaries (Laurus Generics Inc. for the US, Laurus Generics GmbH for the EU, Laurus Generics SA for Africa), participation in international pharmaceutical tenders (notably the Global Fund for ARV supply), and dedicated contract manufacturing for animal health and agrochemical companies. The company holds USFDA, WHO, EMA, UK MHRA, TGA, ANVISA, and KFDA certifications, with 1,400+ quality audits completed across facilities. In FY26, Laurus reported revenue of ₹6,813 crore (23% YoY growth), EBITDA of ₹1,826 crore (26.8% margin), and net profit of ₹889 crore (148% YoY growth), with CDMO revenue specifically growing 36% to ₹2,080 crore.

The company's go-to-market combines direct enterprise sales engagement with global pharmaceutical innovators for CDMO contracts, channel partnerships through its generics subsidiaries, and participation in institutional procurement tenders. It has expanded into advanced therapies through investments in ImmunoACT (CAR-T cell therapy, ~33.86% stake) and an IIT Kanpur collaboration for AAV gene therapy, and has committed ₹3,000 crore in capex over two years primarily for CDMO, peptides, fermentation, and advanced therapy capacity, with a stated goal of CDMO reaching 50% of revenue by FY29.

Short descriptiontext

Laurus Labs is a Hyderabad-based, publicly listed pharmaceutical manufacturer offering integrated API manufacturing, finished dosages, and CDMO services to global pharmaceutical innovators and generic drug companies across 15 manufacturing sites, with growing presence in biologics, cell/gene therapy, and rare disease therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices16 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Active Pharmaceutical Ingredients, Contract Development Services, Generic Finished Dosages, Biopharmaceutical Manufacturing, Pharmaceutical CDMO
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model7 records
1CDMO (Contract Development and Manufacturing)
TypeManaged Services
Description

Provides end-to-end contract manufacturing services to global pharmaceutical companies including chemical process development, API manufacturing, and finished dosage form manufacturing. Revenue grew 36% to ₹2,080 crore in FY26, targeting 50% revenue contribution by FY29.

lauruslabs.com
2Generic APIs and Intermediates
TypeOne Time License
Description

Manufactures and supplies generic active pharmaceutical ingredients including anti-retrovirals, oncology, cardiovascular, and diabetes therapies to global markets.

lauruslabs.com
3Finished Dosage Forms (Generics)
TypeOne Time License
Description

Vertically integrated formulation manufacturing with 10 billion unit capacity for solid oral dosages, serving US, EU, and emerging markets through subsidiary companies.

lauruslabs.com
4Anti-retroviral (ARV) Products
TypeOne Time License
Description

Global leader in ARV APIs and intermediates, with strategic partnership with Global Fund for supply of combination HIV medications to developing nations.

lauruslabs.com
5Biologics and Biotechnology
TypeManaged Services
Description

Through Laurus Bio subsidiary - precision fermentation CDMO services for recombinant proteins, growth factors, and cell-culture media for healthcare, food, nutrition markets.

lauruslabs.com
6Rare Disease Therapeutics
TypeOne Time License
Description

Manufactures and commercializes specialty drugs for Wilson's disease, Tyrosinemia, urea cycle disorders, and Gaucher disease in Indian market.

lauruslabs.com
7Non-Human Ingredients (Animal Health & Agrochemicals)
TypeManaged Services
Description

Through Laurus Synthesis - dedicated CDMO services for animal health ingredients and agrochemical active ingredients from separate manufacturing facilities.

lauruslabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Brand1 of 4 records shown
1TriLaWil
Description

Trientine Tetrahydrochloride 333mg - treatment for Wilson's disease

lauruslabs.com
+3 more records
Core offering1 text field

Laurus Labs is a publicly listed Indian pharmaceutical manufacturer headquartered in Hyderabad, India, founded in 2005. The company manufactures and supplies active pharmaceutical ingredients (APIs), finished dosage formulations, and biopharmaceutical products, and also provides contract development and manufacturing organization (CDMO) services to global pharmaceutical customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CDMO revenue grew 36% to ₹2,080 crore in FY26
+4 more records
Product overview1 text field

Laurus Labs is a research-driven pharmaceutical manufacturing organization offering an integrated portfolio of products and services. The company operates across five core product segments: Pharmaceutical Ingredients (APIs including anti-retroviral, oncology, cardiovascular APIs), Finished Dosages (oral solid dosages with 10 billion unit capacity), Biologics & Biotechnology (through subsidiary Laurus Bio), Non-Human Ingredients (Animal Health and Agrochemicals), and Rare Disease Therapeutics (TriLaWil, LASINONE, AMMOBULA, Larglustat). The company provides CDMO services through Laurus Synthesis and global reach via subsidiaries Laurus Generics GmbH (Europe) and Laurus Generics Inc. (USA). The business model combines in-house API development with contract manufacturing services for global pharmaceutical companies.

Scale indicator23 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-25
Description

Joint venture agreement for generic formulations development and commercialization in Indian market, leveraging combined capabilities in API manufacturing and formulation development.

2IIT Kanpur (Department of Biological Sciences and Bioengineering)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-19
Description

Memorandum of Agreement for novel gene therapy assets development. Collaboration focuses on AAV vector technology and other gene therapy platforms for treating unmet medical needs in India.

lauruslabs.com
3MPP (Medicine Patent Pool)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-21
Description

Agreement to manufacture Molnupiravir, oral COVID-19 antiviral medication, expanding access to COVID treatments in developing markets.

lauruslabs.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-19
Description

CAR-T cell therapy company in which Laurus holds substantial minority stake (~33.86%). ImmunoACT is developing India's first CART therapy for blood cancers and benefits from Laurus investments in 2021 and 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-14
Description

Agreement to accelerate development of best-in-class second- and third-line HIV medication for children, supporting pediatric ARV formulations development.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-07-22
Description

Exclusive distribution partnership for US market launches including Pregabalin Capsules and other generic formulations. Rising serves as the exclusive US distributor for Laurus products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-26
Description

Strategic partnership for supply of ARV combination medicines for HIV/AIDS treatment in developing nations. Laurus has previously executed major tender orders and delivered ahead of schedule for Global Fund.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

Partnership to launch improved triple combination HIV drug in South Africa. Laurus acquired Aspen's South African subsidiary (Laurus Generics SA) to strengthen African market presence.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-10-23
Description

Acquisition of HBV ANDA from Laurus Labs by CASI Pharmaceuticals, transferring rights to certain generic product in US market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian pharma with integrated API and finished dose operations, biologics (through subsidiary biologics business), and global generics footprint. Comparable to Laurus on integrated manufacturing, biologics/CDMO, and global regulatory track record.

2Syngene International
TypeDirect peer
Description

India's largest dedicated CDMO offering end-to-end contract development and manufacturing for small and large molecules. Highly comparable to Laurus's CDMO trajectory, innovator client base, and biologics expansion.

TypeDirect peer
Description

Major Indian pharma with strong ARV franchise and global HIV/AIDS supply programs. Highly comparable to Laurus on ARV API leadership, Global Fund/government procurement partnerships, and emerging market presence.

TypeDirect peer
Description

Indian biopharmaceutical company with biologics CDMO services and fermentation capabilities. Comparable to Laurus Bio on precision fermentation, recombinant proteins, and biologics manufacturing scale.

5Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharmaceutical company with specialty, generics, and API operations. Broadly comparable as an Indian pharma incumbent with global manufacturing footprint, though not a focused CDMO peer.

TypeDirect peer
Description

Indian pharma CDMO with strong high-potency API and contract manufacturing capabilities. Comparable to Laurus on high-potency manufacturing differentiation, CDMO services, and integrated pharma solutions.

TypeDirect peer
Description

Integrated Indian pharma with API, finished dosage, biologics, and vaccines operations. Comparable to Laurus on integrated API-to-formulation manufacturing, US market presence, and biologics ambitions.

TypeDirect peer
Description

Leading Indian API manufacturer with strong CDMO exposure and USFDA-inspected facilities. Directly comparable to Laurus in API scale, regulatory track record, and custom synthesis/CDMO services to global pharma innovators.

TypeDirect peer
Description

Large Indian pharma with vertically integrated API and finished dosage manufacturing, strong ARV franchise, and US generics presence. Directly comparable to Laurus in API-to-FDF integration and US market commercialization through subsidiaries.

TypeDirect peer
Description

Indian pharma with strong API and finished dosage manufacturing operations and US formulations presence. Comparable to Laurus on API manufacturing scale, US generic formulations, and emerging complex generics pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laurus Labs

Laurus Labs is a Hyderabad-based, publicly listed pharmaceutical manufacturer offering integrated API manufacturing, finished dosages, and CDMO services to global pharmaceutical innovators and generic drug companies across 15 manufacturing sites, with growing presence in biologics, cell/gene therapy, and rare disease therapeutics.

What Laurus Labs does

Laurus Labs Limited is a Hyderabad-based, publicly listed pharmaceutical manufacturer founded in 2005 that operates an integrated value chain spanning active pharmaceutical ingredient (API) development, finished dosage form manufacturing, and contract development and manufacturing (CDMO) services. The company is a global leader in anti-retroviral (ARV) APIs and operates 15 manufacturing sites across approximately 230 acres in Visakhapatnam with 8,200+ kiloliters of reactor capacity and 12 billion tablet/capsule annual capacity. Its portfolio is organized across five segments: pharmaceutical ingredients (ARV, oncology, cardiovascular, diabetes APIs), finished dosages, biologics and biotechnology (through subsidiary Laurus Bio's precision fermentation), non-human ingredients (animal health and agrochemicals through Laurus Synthesis), and rare disease therapeutics marketed in India under brands including TriLaWil, LASINONE, AMMOBULA, and Larglustat.

Laurus derives revenue through multiple streams: CDMO services for global pharmaceutical innovators, generic API and intermediate supply, finished dosage commercialization via wholly-owned subsidiaries (Laurus Generics Inc. for the US, Laurus Generics GmbH for the EU, Laurus Generics SA for Africa), participation in international pharmaceutical tenders (notably the Global Fund for ARV supply), and dedicated contract manufacturing for animal health and agrochemical companies. The company holds USFDA, WHO, EMA, UK MHRA, TGA, ANVISA, and KFDA certifications, with 1,400+ quality audits completed across facilities. In FY26, Laurus reported revenue of ₹6,813 crore (23% YoY growth), EBITDA of ₹1,826 crore (26.8% margin), and net profit of ₹889 crore (148% YoY growth), with CDMO revenue specifically growing 36% to ₹2,080 crore.

The company's go-to-market combines direct enterprise sales engagement with global pharmaceutical innovators for CDMO contracts, channel partnerships through its generics subsidiaries, and participation in institutional procurement tenders. It has expanded into advanced therapies through investments in ImmunoACT (CAR-T cell therapy, ~33.86% stake) and an IIT Kanpur collaboration for AAV gene therapy, and has committed ₹3,000 crore in capex over two years primarily for CDMO, peptides, fermentation, and advanced therapy capacity, with a stated goal of CDMO reaching 50% of revenue by FY29.

Laurus Labs firmographics

Firmographics
Name
Laurus Labs
Legal name
Laurus Labs Limited
Website
https://lauruslabs.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Laurus Labs is a Hyderabad-based, publicly listed pharmaceutical manufacturer offering integrated API manufacturing, finished dosages, and CDMO services to global pharmaceutical innovators and generic drug companies across 15 manufacturing sites, with growing presence in biologics, cell/gene therapy, and rare disease therapeutics.
Ownership category
akta.pro rank

Where Laurus Labs is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices16 records

Markets served

Laurus Labs business model

Business model

Revenue model

  1. CDMO (Contract Development and Manufacturing): Provides end-to-end contract manufacturing services to global pharmaceutical companies including chemical process development, API manufacturing, and finished dosage form manufacturing. Revenue grew 36% to ₹2,080 crore in FY26, targeting 50% revenue contribution by FY29.
  2. Generic APIs and Intermediates: Manufactures and supplies generic active pharmaceutical ingredients including anti-retrovirals, oncology, cardiovascular, and diabetes therapies to global markets.
  3. Finished Dosage Forms (Generics): Vertically integrated formulation manufacturing with 10 billion unit capacity for solid oral dosages, serving US, EU, and emerging markets through subsidiary companies.
  4. Anti-retroviral (ARV) Products: Global leader in ARV APIs and intermediates, with strategic partnership with Global Fund for supply of combination HIV medications to developing nations.
  5. Biologics and Biotechnology: Through Laurus Bio subsidiary - precision fermentation CDMO services for recombinant proteins, growth factors, and cell-culture media for healthcare, food, nutrition markets.
  6. Rare Disease Therapeutics: Manufactures and commercializes specialty drugs for Wilson's disease, Tyrosinemia, urea cycle disorders, and Gaucher disease in Indian market.
  7. Non-Human Ingredients (Animal Health & Agrochemicals): Through Laurus Synthesis - dedicated CDMO services for animal health ingredients and agrochemical active ingredients from separate manufacturing facilities.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Laurus Labs product offering

Product offering

Core offering

Laurus Labs is a publicly listed Indian pharmaceutical manufacturer headquartered in Hyderabad, India, founded in 2005. The company manufactures and supplies active pharmaceutical ingredients (APIs), finished dosage formulations, and biopharmaceutical products, and also provides contract development and manufacturing organization (CDMO) services to global pharmaceutical customers.

Product overview

Laurus Labs is a research-driven pharmaceutical manufacturing organization offering an integrated portfolio of products and services. The company operates across five core product segments: Pharmaceutical Ingredients (APIs including anti-retroviral, oncology, cardiovascular APIs), Finished Dosages (oral solid dosages with 10 billion unit capacity), Biologics & Biotechnology (through subsidiary Laurus Bio), Non-Human Ingredients (Animal Health and Agrochemicals), and Rare Disease Therapeutics (TriLaWil, LASINONE, AMMOBULA, Larglustat). The company provides CDMO services through Laurus Synthesis and global reach via subsidiaries Laurus Generics GmbH (Europe) and Laurus Generics Inc. (USA). The business model combines in-house API development with contract manufacturing services for global pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • TriLaWil: Trientine Tetrahydrochloride 333mg - treatment for Wilson's disease
  • LASINONE
  • AMMOBULA
  • Larglustat

Quantifiable outcome

  • CDMO revenue grew 36% to ₹2,080 crore in FY26
  • +4 more outcomes

Companies that use Laurus Labs

Customer profile

Named customers7 records

Segments5 records

Laurus Labs technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Laurus Labs partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • KRKA Pharma Private LimitedcoreStrategic or Co-development Partner · 25 January 2024Joint venture agreement for generic formulations development and commercialization in Indian market, leveraging combined capabilities in API manufacturing and formulation development.
  • IIT Kanpur (Department of Biological Sciences and Bioengineering)coreStrategic or Co-development Partner · 19 June 2023Memorandum of Agreement for novel gene therapy assets development. Collaboration focuses on AAV vector technology and other gene therapy platforms for treating unmet medical needs in India.
  • MPP (Medicine Patent Pool)coreStrategic or Co-development Partner · 21 November 2021Agreement to manufacture Molnupiravir, oral COVID-19 antiviral medication, expanding access to COVID treatments in developing markets.
  • ImmunoACT (Immuno-adoptive Cell Therapy Private Limited)coreStrategic or Co-development Partner · 19 November 2021CAR-T cell therapy company in which Laurus holds substantial minority stake (~33.86%). ImmunoACT is developing India's first CART therapy for blood cancers and benefits from Laurus investments in 2021 and 2023.
  • Unitaid and Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 14 September 2021Agreement to accelerate development of best-in-class second- and third-line HIV medication for children, supporting pediatric ARV formulations development.
  • Rising PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 22 July 2019Exclusive distribution partnership for US market launches including Pregabalin Capsules and other generic formulations. Rising serves as the exclusive US distributor for Laurus products.
  • Global FundcoreStrategic or Co-development Partner · 26 March 2019Strategic partnership for supply of ARV combination medicines for HIV/AIDS treatment in developing nations. Laurus has previously executed major tender orders and delivered ahead of schedule for Global Fund.
  • Aspen PharmacaremajorStrategic or Co-development Partner · 1 December 2018Partnership to launch improved triple combination HIV drug in South Africa. Laurus acquired Aspen's South African subsidiary (Laurus Generics SA) to strengthen African market presence.
  • CASI PharmaceuticalsminorStrategic or Co-development Partner · 23 October 2018Acquisition of HBV ANDA from Laurus Labs by CASI Pharmaceuticals, transferring rights to certain generic product in US market.

Scale indicators23 records

Recent moves7 records

Expansion highlights5 records

Laurus Labs competitors and assessment

Company assessment

Direct peers

  • Dr. Reddy's Laboratories: Indian pharma with integrated API and finished dose operations, biologics (through subsidiary biologics business), and global generics footprint. Comparable to Laurus on integrated manufacturing, biologics/CDMO, and global regulatory track record.
  • Syngene International: India's largest dedicated CDMO offering end-to-end contract development and manufacturing for small and large molecules. Highly comparable to Laurus's CDMO trajectory, innovator client base, and biologics expansion.
  • Cipla: Major Indian pharma with strong ARV franchise and global HIV/AIDS supply programs. Highly comparable to Laurus on ARV API leadership, Global Fund/government procurement partnerships, and emerging market presence.
  • Biocon: Indian biopharmaceutical company with biologics CDMO services and fermentation capabilities. Comparable to Laurus Bio on precision fermentation, recombinant proteins, and biologics manufacturing scale.
  • Piramal Pharma: Indian pharma CDMO with strong high-potency API and contract manufacturing capabilities. Comparable to Laurus on high-potency manufacturing differentiation, CDMO services, and integrated pharma solutions.
  • Cadila Healthcare (Zydus): Integrated Indian pharma with API, finished dosage, biologics, and vaccines operations. Comparable to Laurus on integrated API-to-formulation manufacturing, US market presence, and biologics ambitions.
  • Divis Laboratories: Leading Indian API manufacturer with strong CDMO exposure and USFDA-inspected facilities. Directly comparable to Laurus in API scale, regulatory track record, and custom synthesis/CDMO services to global pharma innovators.
  • Aurobindo Pharma: Large Indian pharma with vertically integrated API and finished dosage manufacturing, strong ARV franchise, and US generics presence. Directly comparable to Laurus in API-to-FDF integration and US market commercialization through subsidiaries.
  • Lupin: Indian pharma with strong API and finished dosage manufacturing operations and US formulations presence. Comparable to Laurus on API manufacturing scale, US generic formulations, and emerging complex generics pipeline.

Broad incumbents

  • Sun Pharmaceutical Industries: India's largest pharmaceutical company with specialty, generics, and API operations. Broadly comparable as an Indian pharma incumbent with global manufacturing footprint, though not a focused CDMO peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Laurus Labs social profiles

Digital presence

Laurus Labs compliance and trust

Trust signal

Compliance12 records

Laurus Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laurus Labs leadership team

Management profile

Number of profiles

Laurus Labs subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Laurus Labs funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laurus Labs M&A and investment

M&A and investment

M&A2 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laurus Labs

What does Laurus Labs do?

Laurus Labs is a publicly listed Indian pharmaceutical manufacturer headquartered in Hyderabad, India, founded in 2005. The company manufactures and supplies active pharmaceutical ingredients (APIs), finished dosage formulations, and biopharmaceutical products, and also provides contract development and manufacturing organization (CDMO) services to global pharmaceutical customers.

Is Laurus Labs a public or private company?

Laurus Labs is a public company. It is currently operating.

When was Laurus Labs founded?

Laurus Labs was founded in 2005. It employs 1,001 to 5,000 people.

Where is Laurus Labs based?

Laurus Labs is headquartered in Hyderabad, India, in the Asia region.

How does Laurus Labs make money?

Seven revenue lines are on record. CDMO (Contract Development and Manufacturing) is the primary driver. The others are generic APIs and Intermediates, finished Dosage Forms (Generics), anti-retroviral (ARV) Products, biologics and Biotechnology, rare Disease Therapeutics and non-Human Ingredients (Animal Health & Agrochemicals).

Who are Laurus Labs's main competitors?

Direct peers on record are Dr. Reddy's Laboratories, Syngene International, Cipla, Biocon, Piramal Pharma, Cadila Healthcare (Zydus), Divis Laboratories, Aurobindo Pharma and Lupin. Sun Pharmaceutical Industries is listed as a broad incumbent.

Does Laurus Labs have an API?

No public API is recorded for Laurus Labs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXLaurus Labs promoters sell 20.7 lakh shares for charitable purposesLaurus Labs promoters sold a combined 20.7 lakh equity shares in November 2026 for charitable purposes. The company stated no further stake sale plans exist among promoters and that the transaction does not affect fundamentals.CNBCTV18Laurus Labs sees strong CDMO growth ahead, targets 50% revenue contribution by FY30 - CNBC TV18Laurus Labs promoter group sold about 20 lakh shares to retire debt and support philanthropy, with no further stake sales planned. The company targets CDMO revenue to reach at least 50% of total by FY30, with gross margins and EBITDA margins expected to remain at similar levels.CNBCTV18Laurus Labs shares recover more than 50% of Monday's fall after promoter rules out further stake sale - CNBC TV18Laurus Labs promoters ruled out further stake sales, and shares recovered over 50% of Monday's fall, gaining 4% on Tuesday. The drop followed a promoter sale of nearly 20 lakh shares on November 11. Management cited debt reduction and philanthropy as reasons, with capex planned at ₹2,000 crore for FY27.Business News TodayLaurus Labs shares rise 3.5% as promoter says no further plans for stake sale- Moneycontrol.comLaurus Labs shares rose 3.5% on November 17 after promoter Satyanarayana Chava said no further stake sale plans. The company's stock had fallen 9% earlier after Chava and CFO sold shares for Rs 500 crore. Laurus also announced acquisitions of stakes in Galenvs Science and SI&C Resins.The Times of IndiaLaurus Labs shares rally over 5% as promoters rule out further stake saleLaurus Labs shares rose over 5% after promoter Satyanarayana Chava said no further stake sale, citing personal debt and charity. Q2 revenue hit Rs 2,206 crore, up 33% year-on-year, with net profit surging 126% to Rs 441 crore. The company plans Rs 2,000 crore in FY27 capex funded via internal accruals.Business StandardPharma stocks under pressure; Laurus, Sai Life, Divi's slide up to 10%Pharmaceutical stocks fell up to 10% on the NSE on Monday, with Laurus Labs down 10% and Sai Life down 7.4%. Jefferies said Indian CRDMOs with strong Big Pharma ties will outperform, citing Divi's and Laurus as strong on scale and execution.CNBCTV18Explained - Why Laurus Labs share price fell 10% on Monday - CNBC TV18Laurus Labs shares fell 10% on Monday after promoter Satyanarayana Chava and LEVEN HOLDINGS sold over 20 lakh shares in the open market. The stock, which had touched a record high of ₹2,488, traded at ₹2,202.2, down 9.1% from the previous close.Dealroom.coLaurus Labs buys 60% of Canada's Galenvs for $3.75M to expand oligonucleotides | Dealroom NewsLaurus Labs agreed to acquire a 60% stake in Galenvs for $3.75 million, valuing the Montreal-based oligonucleotide firm at $3.5 million pre-money. The deal, announced October 29, 2026, includes two tranches and gives Laurus a North American research foothold. Laurus also acquired a 52% stake in SI&C Resins for $4.35 million.Business News TodayLaurus Labs shares fall 3.5% as promoters sell shares worth Rs 500 crore- Moneycontrol.comLaurus Labs shares fell 3.5% on November 16 after promoters sold 20 lakh shares worth Rs 500 crore. The company reported Q2 net profit of Rs 441 crore, up from Rs 195 crore a year ago, and has agreed to acquire stakes in Galenvs Science and SI&C Resins.The Times of IndiaLaurus Labs shares tumble nearly 9% after promoters sell stake worth Rs 500 crore; multibagger stock up 122% in one yearLaurus Labs shares fell nearly 9% after promoters sold over 20 lakh shares worth Rs 486.68 crore on November 11. The company reported Q2 revenue of Rs 2,206 crore, up 33% year-on-year, and net profit of Rs 441 crore, up 126%. The stock has gained over 128% in one year.